Future Directions in Treatment of Chronic Lymphocytic Leukemia (CLL) with BTK Inhibitors

Experts in hematology/oncology share key insight on the treatment of CLL, including the use of BTK inhibitors and the critical role of pharmacists in disease management.

EP. 1: Individualized Treatment Approach for the Management of CLL

February 24th 2022

Bhavesh Shah, RPh, BCOP, and Ryan Jacobs, MD, share considerations for approaching an individualized treatment regimen for patients with CLL.

EP. 2: Role of Chemotherapy in Frontline CLL Treatment

February 24th 2022

Dr Ryan Jacobs evaluates the use of chemotherapy options for first-line treatment of CLL.

EP. 3: Goals of Therapy for CLL

March 10th 2022

Experts in hematology/oncology discuss goals of therapy and optimal treatment selection for patients with chronic lymphocytic leukemia.

EP. 4: Treatment Selection Among BTK Inhibitors for First-Line CLL Treatment

March 10th 2022

Ryan Jacobs, MD, and Bhavesh Shah, RPh, BCOP, provide insight on considerations when choosing a BTK inhibitor for initial treatment of chronic lymphocytic leukemia.

EP. 5: Phase 3 SEQUOIA Study: Zanubrutinib in Treatment-Naïve CLL

March 10th 2022

Dr Ryan Jacobs, MD, leads a review of the phase 3 SEQUOIA trial presented at ASH 2021 evaluating the use of zanubrutinib for previously untreated CLL and discusses the management of adverse events with BTK inhibitors.

EP. 6: BTK Inhibitors: Switching Therapies in CLL

March 10th 2022

Key opinion leaders in hematology-oncology share recommendations on switching from first-generation BTK inhibitors to next-generation BTK inhibitors for the management of patients with CLL.

EP. 7: Role of Pharmacists in the Management of CLL

March 17th 2022

Ryan Jacobs, MD, and Bhavesh Shah, RPh, BCOP, comment on the role of pharmacists in clinical practice for managing patients with CLL.

EP. 8: Future Directions for the Treatment of CLL

March 17th 2022

Bhavesh Shah, RPh, BCOP, and Ryan Jacobs, MD, discuss emerging agents in the pipeline and the future treatment landscape for CLL.